Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 9:15:367-374.
doi: 10.2147/JEP.S427615. eCollection 2023.

The Efficacy of Topical Formulation Containing Ciplukan (Physalis angulata Linn.) in Modulating Interleukin-17 and Interferon Gamma Expression in Mice (Mus musculus) Psoriasis Model

Oki Suwarsa  1 , Hartati Purbo Dharmadji  1 , Enny Rohmawaty  2 , Shela Mareta  1 , Hendra Gunawan  1 , Reiva Farah Dwiyana  1 , Pati Aji Achdiat  1 , Endang Sutedja  1 , Miranti Pangastuti  1
Affiliations

The Efficacy of Topical Formulation Containing Ciplukan (Physalis angulata Linn.) in Modulating Interleukin-17 and Interferon Gamma Expression in Mice (Mus musculus) Psoriasis Model

Oki Suwarsa et al. J Exp Pharmacol. .

Abstract

Background: Interleukin 17 (IL-17) and interferon gamma (IFN-γ) play a role in the pathogenesis of psoriasis vulgaris (PV). Topical corticosteroids are still utilised as first-line therapy for mild to moderate PV. However, long-term use of corticosteroid is associated with various side effects. Physalis angulata Linn. (Ciplukan) possesses anti-inflammatory properties that could serve as a potential alternative topical therapy for PV.

Objective: To assess the efficacy of topical ciplukan as an anti-inflammatory agent targeting the expression of IL-17 and IFN-γ.

Methods: Psoriasis was induced using imiquimod cream, therefore divided into five groups. Group I, the psoriasis control group, received only imiquimod cream. Groups C1 and C2 received imiquimod cream followed by a mixture of Ciplukan and vaseline in a 1:2 and 1:4 ratio, respectively. Group M, the standard therapy group, received imiquimod cream, followed by mometasone furoate cream. Lastly, group V, the vehicle group, received imiquimod cream followed by vaseline album. Expression of IL-17 and IFN-γ in mice's skin tissue was analysed using reverse transcription polymerase chain reaction (RT-PCR) after seven days of treatment.

Results: The mean expression of IL-17 in Group C1 (22.60) was significantly lower (p = 0.012) than in the psoriasis control group (23.60), and there was no significant difference (p = 0.613) in Group M (22.41). The mean expression of IFN-γ in Group C1 (26.97) and Group C2 (27.03) was also significantly lower (p = 0.026 and p = 0.026, respectively) than Group I (28.80), and there was no significant difference (p = 0.180 and p = 0.093, respectively) than Group M (26.03).

Conclusion: Expression of IL-17 and IFN-γ in the ciplukan group is lower than in the psoriasis control group, and there is no significant difference compared to the standard therapy group.

Keywords: IFN-γ; IL-17; Physalis angulata Linn; psoriasis vulgaris.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Clinical image of skin lesion after treatment. (a) Group I, psoriasis control group (5% imiquimod cream), Modified PASI 6. (b) Group C1 (5% imiquimod cream followed by a mixture of Ciplukan and vaseline in a 1:2 ratio), Modified PASI 1. (c) Group C2 (5% imiquimod cream followed by a mixture of Ciplukan and vaseline in a 1:4 ratio), Modified PASI 1. (d) Group M (5% imiquimod cream followed by mometasone furoate cream), Modified PASI 1. (e) Group V, vehicle group (5% imiquimod cream followed by vaselin album), Modified PASI 4.
See this image and copyright information in PMC

References

    1. Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel DJ, Wolff K. Fitzpatrick’s Dermatology. 8th ed. New York: McGraw-Hill Education; 2008.
    1. Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology. 3rd ed. Edinburgh: Mosby Elsevier; 2008.
    1. Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018;45:264–272. doi:10.1111/1346-8138.14139 - DOI - PubMed
    1. Raychaudhuri SP, Raychaudhuri S, Bagchi D. Psoriasis and Psoriatic Arthritis Pathophysiology, Therapeutic Intervention and Complementary Medicine. 1st ed. Boca Raton: CRC Press; 2018:3–8.
    1. Dewi DAPN, Indira IG. Insiden dan profil psoriasis di poliklinik kulit dan kelamin Rumah Sakit Umum Pusat Sanglah Denpasar periode Januari 2012 sampai Desember 2014 [Incidence and profile of psoriasis in dermatovenereology clinic at Sanglah Central General Hospital Denpasar in January 2012 to December 2014]. E J Med Udayana. 2018;7(9):1–7. Indonesian.